VanEck Pharmaceutical ETF $PPH Holdings Trimmed by Adamsbrown Wealth Consultants LLC

Adamsbrown Wealth Consultants LLC decreased its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 30.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 136,899 shares of the company’s stock after selling 59,077 shares during the period. VanEck Pharmaceutical ETF comprises 3.4% of Adamsbrown Wealth Consultants LLC’s portfolio, making the stock its 10th biggest position. Adamsbrown Wealth Consultants LLC’s holdings in VanEck Pharmaceutical ETF were worth $12,370,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of PPH. CWM LLC raised its holdings in shares of VanEck Pharmaceutical ETF by 167.9% during the second quarter. CWM LLC now owns 375 shares of the company’s stock valued at $33,000 after purchasing an additional 235 shares during the last quarter. Creative Financial Designs Inc. ADV raised its holdings in shares of VanEck Pharmaceutical ETF by 18.1% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 2,129 shares of the company’s stock valued at $187,000 after purchasing an additional 327 shares in the last quarter. Westside Investment Management Inc. acquired a new position in shares of VanEck Pharmaceutical ETF during the second quarter worth $208,000. Jefferies Financial Group Inc. purchased a new stake in VanEck Pharmaceutical ETF in the second quarter valued at approximately $287,000. Finally, Harbour Investments Inc. boosted its holdings in VanEck Pharmaceutical ETF by 9.7% during the second quarter. Harbour Investments Inc. now owns 4,450 shares of the company’s stock worth $391,000 after buying an additional 394 shares in the last quarter.

VanEck Pharmaceutical ETF Price Performance

NASDAQ PPH opened at $107.27 on Wednesday. The firm’s 50-day moving average is $103.00 and its two-hundred day moving average is $94.53. VanEck Pharmaceutical ETF has a 12 month low of $77.67 and a 12 month high of $108.26. The stock has a market capitalization of $1.22 billion, a P/E ratio of 20.21 and a beta of 0.54.

VanEck Pharmaceutical ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 29th were given a $0.3106 dividend. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, December 29th.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.